Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

NCT07080242 is registered in ClinicalTrials.gov with SystImmune Inc. as lead sponsor.

NCT NCT07080242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07080242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
Lead sponsor
SystImmune Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 28, 2025
Completion date
December 31, 2027
Enrollment
120 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced extrapulmonary neuroendocrine carcinoma, locally advanced large cell neuroendocrine carcinoma of the lung, locally advanced merkel cell carcinoma, locally advanced neuroendocrine prostate cancer, locally advanced poorly differentiated gastroenteropancreatic neuroendocrine, metastatic advanced merkel cell carcinoma, metastatic advanced poorly differentiated gastroenteropancreatic neuroendocrine carcinoma, metastatic large cell neuroendocrine carcinoma of the lung, metastatic neuroendocrine prostate cancer, neuroendocrine cancer, small cell lung cancer metastatic or locally advanced